The epidemiology of hepatocellular carcinoma (HCC) is characterized by dynamic temporal
trends, several major established (ie, HCV, HBV, alcohol) and emerging (ie, diabetes …

The incidence of hepatocellular carcinoma (HCC) has almost tripled since the early 1980s in
the United States, where it is the fastest rising cause of cancerrelated deaths. 1 According to …

In the treatment of chronic hepatitis B (CHB), the ultimate goal is preventing hepatitis B virus
(HBV)-associated liver disease, including hepatocellular carcinoma (HCC). Recently …

Entecavir is a potent antiviral agent with high genetic barrier to resistance, hence it is
currently recommended as first‐line antiviral therapy for chronic hepatitis B (CHB). The aim …

Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials
investigating the efficacy of pegylated interferon alpha (PEG‐IFNa) showed HDV RNA …

Background & Aims Progression of liver fibrosis still occurs in some patients with chronic
hepatitis B virus (HBV) infection despite antiviral therapy. We aimed to identify risk factors for …

Abstract Background & Aims Oral antiviral therapy may reduce the disease progression of
chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long‐term …

Background Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian
entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk …

Liver cancer, of which hepatocellular carcinoma (HCC) is the dominant variety, represents
the fourth leading cause of cancer deaths worldwide. The geographic map of the incidence …

Chronic hepatitis B virus (HBV) infection follows a dynamic and variable course. At different
stages in the disease, hepatitis flares might occur, which can be challenging to predict and …